Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$61.99 USD
+0.22 (0.36%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $62.00 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CDTX 61.99 +0.22(0.36%)
Will CDTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Other News for CDTX
Paradigm Biocapital Advisors LP Acquires 1,128,613 Shares in Cidara Therapeutics Inc
Cidara Therapeutics price target raised by $40 at RBC Capital, here's why
Cidara Therapeutics price target raised by $40 at RBC Capital, here's why
Cidara Therapeutics Inc (CDTX) Announces Upcoming Q2 2025 Financial Results Release | CDTX ...
Cidara Therapeutics (CDTX) Target Price Raised by Guggenheim | CDTX Stock News